- Olema Oncology (OLMA, Financial) reveals promising preclinical data of OP-3136, a novel KAT6 inhibitor, showing significant anti-tumor activity in ovarian, prostate, and NSCLC models.
- OP-3136 demonstrated sustained tumor regression and synergy with existing treatments, indicating potential applicability beyond breast cancer.
- Patient recruitment is ongoing for Phase 1 trials to further evaluate OP-3136 as monotherapy and in combination regimens for various solid tumors.
Olema Oncology (OLMA) has announced the presentation of compelling preclinical data for OP-3136, showcasing its notable anti-tumor activity in ovarian, prostate, and non-small cell lung cancer (NSCLC) models. These findings were shared at the 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago, Illinois.
OP-3136, a selective KAT6 inhibitor, exhibited potent anti-proliferative effects across multiple cancer cell lines. In particular, the OVCAR3 ovarian cancer model demonstrated sustained tumor regression over a 28-day period, underscoring the drug's potential efficacy as a therapeutic option. In the LCLC-97TM1 NSCLC model, OP-3136 showed tumor growth inhibition on par with ribociclib, an established CDK4/6 inhibitor, suggesting similar clinical potential.
Furthermore, in the 22Rv1 prostate cancer model, OP-3136 inhibited tumor growth in a dose-dependent manner. The preclinical trials also explored combination therapies, where OP-3136 showed synergistic effects with ribociclib in NSCLC and docetaxel in prostate cancer models, indicating promising combination strategies to enhance treatment outcomes.
The company has initiated a Phase 1 clinical trial for OP-3136, with active recruitment for patients across various solid tumor types. This trial aims to further assess its efficacy as both a standalone treatment and in combination regimens, expanding the potential therapeutic applications of OP-3136 beyond breast cancer.
